Which companies are Shandong Wit Dyne Health's closest peers?

The cockpit's peer set: Jenkem Technology (688356.SS), Zevra Therapeutics (ZVRA), Mochida Pharmaceutical (4534.T), Nuvectis Pharma (NVCT), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Achieve Life Sciences (ACHV), Earth (4985.T), Beijing Beilu Pharmaceutical (300016.SZ).

Is Shandong Wit Dyne Health expensive compared with its peers?

On forward p/e it trades at 9.1× against a peer median of 16.4×, 2nd cheapest of 9 in its peer set.

How has Shandong Wit Dyne Health stock performed?

Over six months to 6 Nov 2026 the shares returned -32.5% against -5.6% for the median peer; over one year -40.5%.

← CockpitCompetitor Analysis › 000915.SZ Shandong Wit Dyne Health Co., Ltd. Class AOpen in the cockpit ↗

Shandong Wit Dyne Health Co., Ltd. Class A000915.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Momentum laggard 8

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$687M

US dollars, full cap

Free float

68%

of shares outstanding

$/day

$10.2M

20-day average traded

Fwd P/E

9.1×

forward earnings

ROIC−WACC

+10.0 pp

WACC 6.1%

Hurdle

n/a

no reverse DCF

Next earnings

136 days

22 Mar 2027

Close · CNYCN¥19.54

1D-0.1%

1W-8.8%

1M-18.4%

3M-25.0%

6M-32.5%

YTD-40.9%

1Y-40.5%

ATR %4.0%

52w lowhigh46.0% off high

What Shandong Wit Dyne Health does

Employees: 1,719

Shandong Wit Dyne Health at a glance

Size Shandong Wit Dyne Health (000915.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $687M, the 3104th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥19.54 on 6 Nov 2026.

Performance Over six months the shares fell 32.5%, against -5.6% for the median peer and -16.4% for the China market (cap-weighted) — lowest of 21 in its peer set.

Growth Revenue fell 35.8% over the last twelve months (peer median +14.1%); the operating margin is 36.2% (peer median 10.7%).

Valuation It trades at 9.1× forward earnings against a peer median of 16.4× (2nd cheapest of 9).

Capital Return on invested capital runs 10.0 points above its cost of capital (6.1% WACC).

Next results Next results expected around 22 Mar 2027 (exchange calendar; dates can move).

Relative performance

Six months, rebased to 100: Shandong Wit Dyne Health against the median of its 20 peers (local-currency closes).

Shandong Wit Dyne Health financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CN¥1.51B	CN¥2.20B	CN¥2.10B	CN¥2.45B	CN¥2.31B
Revenue growth	—	+5%	-15%	+6%	—
Gross profit	CN¥1.26B	CN¥1.83B	CN¥1.71B	CN¥2.08B	CN¥1.79B
EBITDA	n/a	CN¥1.24B	CN¥1.18B	CN¥1.34B	CN¥1.21B
Net income	CN¥284M	CN¥535M	CN¥516M	CN¥585M	CN¥527M
Free cash flow	-CN¥7.73M	CN¥1.25B	CN¥915M	CN¥1.15B	CN¥1.13B
Capital expenditure	CN¥15.7M	CN¥48.3M	CN¥43.6M	CN¥50.6M	CN¥89.7M
Total debt	CN¥0	CN¥356,348	CN¥2.86M	CN¥66,955	CN¥9.89M

Quarterly statements and history in the cockpit →

Shandong Wit Dyne Health competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. Shandong Wit Dyne Health is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Shandong Wit Dyne Health is the large dot.

Shandong Wit Dyne Health competitors and peer comparison

How Shandong Wit Dyne Health compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Shandong Wit Dyne Health against its 20 peers (data as of 6 Nov 2026)
Measure	000915.SZ	Peer median	Rank in peer set
1-month return	-18.4%	-4.0%	2nd lowest of 21
6-month return	-32.5%	-5.6%	lowest of 21
Distance from 52-week high	-46.0%	-26.1%	4th lowest of 21
Revenue growth (TTM)	-35.8%	+14.1%	2nd lowest of 17
Operating margin	36.2%	10.7%	3rd highest of 16
Forward P/E	9.1×	16.4×	2nd cheapest of 9
ROIC minus cost of capital	+10.0 pp	-3.3 pp	2nd highest of 14

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	Forward P/E	Req g	Delivered g
Shandong Wit Dyne Health 000915.SZ	China	$687M	-33%	-36%	36%	9.1×	n/a	n/a
Jenkem Technology 688356.SS	China	$686M	-23%	+52%	11%	36.8×	41.4%	+11.2%
Zevra Therapeutics ZVRA	United States	$690M	+4%	+75%	31%	11.8×	0.0%	+51.6%
Mochida Pharmaceutical 4534.T	Japan	$683M	-6%	+15%	9%	15.2×	n/a	n/a
Nuvectis Pharma NVCT	United States	$683M	+79%	n/a	n/a	n/a	n/a	n/a
Hubei Biocause Heilen Pharmaceutical 301211.SZ	China	$682M	-5%	+13%	4%	n/a	n/a	n/a
Achieve Life Sciences ACHV	United States	$692M	+29%	n/a	n/a	n/a	n/a	n/a
Earth 4985.T	Japan	$682M	+6%	+6%	4%	17.7×	-2.5%	-1.8%
Beijing Beilu Pharmaceutical 300016.SZ	China	$692M	-16%	+23%	11%	88.2×	10.3%	+7.9%
Sagimet Biosciences SGMT	United States	$693M	+28%	n/a	n/a	n/a	n/a	n/a
Philogen PHIL.MI	Italy	$694M	-7%	+295%	79%	32.5×	n/a	n/a
Hunan Fangsheng Pharmaceutical 603998.SS	China	$678M	-6%	+10%	19%	12.7×	-2.4%	+6.4%
Center Laboratories 4123.TWO	Taiwan	$676M	-28%	+4%	5%	n/a	50.8%	+16.2%
Bliss GVS Pharma BLISSGVS.NS	India	$698M	+126%	+21%	15%	n/a	37.0%	+10.1%
FDC FDC.NS	India	$672M	+4%	+10%	14%	n/a	25.9%	+10.3%
HeiLongJiang ZBD Pharmaceutical 603567.SS	China	$705M	-29%	-82%	n/a	6.3×	10.5%	-25.1%
Immix Biopharma IMMX	United States	$668M	-17%	n/a	n/a	n/a	n/a	n/a
Zhejiang Wecome Pharmaceutical 300878.SZ	China	$666M	+10%	+40%	-65%	n/a	n/a	n/a
Sun Pharma Advanced Research SPARC.NS	India	$665M	+16%	+3,141%	84%	n/a	n/a	n/a
Hainan Haiyao 000566.SZ	China	$710M	-19%	-18%	-50%	n/a	n/a	n/a
Luoxin Pharmaceuticals Group Stock 002793.SZ	China	$664M	-26%	-10%	-9%	n/a	0.3%	-17.9%

Questions

Which companies are Shandong Wit Dyne Health's closest peers?: The cockpit's peer set: Jenkem Technology (688356.SS), Zevra Therapeutics (ZVRA), Mochida Pharmaceutical (4534.T), Nuvectis Pharma (NVCT), Hubei Biocause Heilen Pharmaceutical (301211.SZ), Achieve Life Sciences (ACHV), Earth (4985.T), Beijing Beilu Pharmaceutical (300016.SZ).
Is Shandong Wit Dyne Health expensive compared with its peers?: On forward p/e it trades at 9.1× against a peer median of 16.4×, 2nd cheapest of 9 in its peer set.
How has Shandong Wit Dyne Health stock performed?: Over six months to 6 Nov 2026 the shares returned -32.5% against -5.6% for the median peer; over one year -40.5%.